Cargando…
P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621481/ http://dx.doi.org/10.1097/01.HS9.0000890604.66330.a0 |
| _version_ | 1784821565380100096 |
|---|---|
| author | Hutchings, Martin Ansell, Stephen M. Connors, Joseph M. Kim, Won Seog Gallamini, Andrea Ramchandren, Radhakrishnan Friedberg, Jonathan W. Advani, Ranjana Evens, Andrew M. Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Eom, Hyeon-Seok Abramson, Jeremy S. Dong, Cassie Campana, Frank Fenton, Keenan Puhlmann, Markus Straus, David J. Radford, John |
| author_facet | Hutchings, Martin Ansell, Stephen M. Connors, Joseph M. Kim, Won Seog Gallamini, Andrea Ramchandren, Radhakrishnan Friedberg, Jonathan W. Advani, Ranjana Evens, Andrew M. Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Eom, Hyeon-Seok Abramson, Jeremy S. Dong, Cassie Campana, Frank Fenton, Keenan Puhlmann, Markus Straus, David J. Radford, John |
| author_sort | Hutchings, Martin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621481 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96214812022-11-01 P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 Hutchings, Martin Ansell, Stephen M. Connors, Joseph M. Kim, Won Seog Gallamini, Andrea Ramchandren, Radhakrishnan Friedberg, Jonathan W. Advani, Ranjana Evens, Andrew M. Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Eom, Hyeon-Seok Abramson, Jeremy S. Dong, Cassie Campana, Frank Fenton, Keenan Puhlmann, Markus Straus, David J. Radford, John Hemasphere Advanced Stages Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621481/ http://dx.doi.org/10.1097/01.HS9.0000890604.66330.a0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Advanced Stages Hutchings, Martin Ansell, Stephen M. Connors, Joseph M. Kim, Won Seog Gallamini, Andrea Ramchandren, Radhakrishnan Friedberg, Jonathan W. Advani, Ranjana Evens, Andrew M. Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Eom, Hyeon-Seok Abramson, Jeremy S. Dong, Cassie Campana, Frank Fenton, Keenan Puhlmann, Markus Straus, David J. Radford, John P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 |
| title | P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 |
| title_full | P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 |
| title_fullStr | P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 |
| title_full_unstemmed | P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 |
| title_short | P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 |
| title_sort | p009: improved overall survival with first-line brentuximab vedotin plus chemotherapy in patients with advanced stage iii/iv classical hodgkin lymphoma: an updated analysis of echelon-1 |
| topic | Advanced Stages |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621481/ http://dx.doi.org/10.1097/01.HS9.0000890604.66330.a0 |
| work_keys_str_mv | AT hutchingsmartin p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT ansellstephenm p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT connorsjosephm p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT kimwonseog p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT gallaminiandrea p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT ramchandrenradhakrishnan p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT friedbergjonathanw p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT advaniranjana p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT evensandrewm p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT smolewskipiotr p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT savagekerryj p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT bartlettnancyl p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT eomhyeonseok p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT abramsonjeremys p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT dongcassie p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT campanafrank p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT fentonkeenan p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT puhlmannmarkus p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT strausdavidj p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 AT radfordjohn p009improvedoverallsurvivalwithfirstlinebrentuximabvedotinpluschemotherapyinpatientswithadvancedstageiiiivclassicalhodgkinlymphomaanupdatedanalysisofechelon1 |